Functional Polymers in Biomedical and Pharmaceutical Applications

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 2066

Special Issue Editor


E-Mail Website1 Website2
Guest Editor
Center for Education and Research on Macromolecules (CERM), Complex and Entangled Systems from Atoms to Materials Research Unit (CESAM-RU), University of Liège, 4000 Liège, Belgium
Interests: biopolymers; polymer scaffolds; smart drug delivery systems

Special Issue Information

Dear Colleagues,

Polymers represent a significant group of biomaterials that are exploited for various biomedical applications. They have been extensively studied and implemented for several pharmaceutical applications, which include smart injectable delivery systems for poorly soluble drugs towards gene transfection. Moreover, with the recent developments in translational medicine, drug- or protein-loaded polymer scaffolds have been specifically designed for regenerative medicine and tissue engineering.

Synthetic or natural polymers are highly flexible in tailoring their physical, chemical, and mechanical properties as well as their degradation kinetics via synthesis or by providing chemical modifications. Therefore, they can be tailor-made to optimize their encapsulation efficiency, to exhibit dedicated stimuli-responsive behaviour, providing smart drug delivery systems, and to tune their biodegradation in order to tailor the release profile and mechanism to the application needs. This Special Issue aims to address how polymer-based drug delivery systems ensure optimal therapeutic efficiency by preserving and precisely delivering therapeutic agents to targeted sites with minimal site effects, releasing them in a controlled and sustained manner according to the patient-specific therapeutic function.

In this Special Issue, original research articles and reviews are welcome.

I look forward to receiving your contributions.

Prof. Dr. Christine Jerome
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural and synthetic polymers
  • biomaterials
  • smart drug delivery system
  • medical device
  • three-dimensional porous scaffolds
  • biodegradable polymer
  • stimuli-responsive polymer
  • targeted drug delivery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 5942 KiB  
Article
PLGA Carriers for Controlled Release of Levofloxacin in Anti-Tuberculosis Therapy
by Evgeny N. Antonov, Sofya N. Andreevskaya, Irina V. Bocharova, Sergei E. Bogorodsky, Larisa I. Krotova, Elena E. Larionova, Alexandra O. Mariyanats, Gennady V. Mishakov, Tatiana G. Smirnova, Larisa N. Chernousova and Vladimir K. Popov
Pharmaceutics 2022, 14(6), 1275; https://doi.org/10.3390/pharmaceutics14061275 - 15 Jun 2022
Cited by 7 | Viewed by 1828
Abstract
Levofloxacin (LFX) is a highly effective anti-tuberculosis drug with a pronounced bactericidal activity against Mycobacterium tuberculosis (Mtb). In this work, an “organic solvent-free” approach has been used for the development of polylactic-co-glycolic acid (PLGA) microparticles and scaffolds containing LFX at a [...] Read more.
Levofloxacin (LFX) is a highly effective anti-tuberculosis drug with a pronounced bactericidal activity against Mycobacterium tuberculosis (Mtb). In this work, an “organic solvent-free” approach has been used for the development of polylactic-co-glycolic acid (PLGA) microparticles and scaffolds containing LFX at a therapeutically significant concentration, providing for its sustained release. To achieve the target, both nonpolar supercritical carbon dioxide and polar supercritical trifluoromethane have been used. By changing the composition, surface morphology, size, and internal structure of the polymer carriers, one can control the kinetics of the LFX release into phosphate buffered saline solutions and physiological media, providing for its acceptable burst and desirable concentration in the prolonged phase. The biocompatibility and bactericidal efficacy of PLGA/LFX carriers assessed both in vitro (against Mtb phagocytosed by macrophages) and in vivo (against inbred BALB/c mice aerogenically infected with Mtb) demonstrated their anti-tuberculosis activity comparable with that of the standard daily intragastric levofloxacin administration. These results make it possible to consider the developed compositions as a promising candidate for anti-tuberculosis control release formulations providing for the further evaluation of their activity against Mtb and their metabolism in vivo over long periods of tuberculosis infection. Full article
(This article belongs to the Special Issue Functional Polymers in Biomedical and Pharmaceutical Applications)
Show Figures

Graphical abstract

Back to TopTop